Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN 2
2023-506268-15-00Phase 3Completed
- Sponsor
- Lyra Therapeutics, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of LYR-210 in chronic rhinosinusitis (CRS) (2 arms), sponsored by Lyra Therapeutics, Inc. Primary endpoint: Change from baseline in 7-day average composite score of the 3 cardinal symptoms (3CS) at Week 24 in participants without nasal polyps. Started Oct 2023; status: completed.
02
Drugs
LYR-210
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on 2023-506268-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506268-15-00.